Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Diabetes Care 29:749 2006
DOI: 10.2337/diacare.29.03.06.dc05-2100
© 2006 by the American Diabetes Association
This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kaplan, S. A.
Right arrow Articles by Crawford, E. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kaplan, S. A.
Right arrow Articles by Crawford, E. D.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Letters: Comments and Responses

Relationship Between Testosterone Levels, Insulin Sensitivity, and Mitochondrial Function in Men

Response to Pitteloud et al.

Steven A. Kaplan, MD1 and E. David Crawford, MD2

1 Columbia University Medical Center, New York, New York
2 University of Colorado Health Sciences Center, Aurora, Colorado

Address correspondence to Steven A. Kaplan, MD, Department of Urology, Weill Cornell Medical College, F9-West, Box 261, 1300 York Ave., New York, NY 10021. E-mail: kaplans{at}med.cornell.edu

We read with interest the excellent study by Pitteloud et al. (1) demonstrating that low serum total testosterone levels are associated with an adverse metabolic profile in aging men and suggesting a novel unifying mechanism for the previously independent observations that low testosterone levels and impaired mitochondrial function promote insulin resistance in these patients. The authors concluded their report by stating that there is a need for evaluation of the potential benefits of androgen supplementation in preventing or treating the metabolic syndrome and/or type 2 diabetes in men.

While we agree with their conclusion, we would like to provide the authors with a cautionary comment regarding the means by which androgen levels should be supplemented in these patients. The most commonly used method to increase androgen levels in aging, hypogonadal men is to administer testosterone supplementation therapy (2). From a urological perspective, a major problem with the use of testosterone supplementation alone in aging men is that the exogenously administered testosterone is metabolized by 5{alpha}-reductase to dihydrotestosterone (DHT). Based on newly emerging data from the National Cancer Institute–sponsored Prostate Cancer Prevention Trial, DHT is a proven risk factor for the development of prostate cancer in aging men (3). Moreover, the use of testosterone supplementation alone in men with low serum testosterone levels has been shown to lead to an elevation in their intraprostatic DHT levels (4).

In light of the potentially serious safety concerns associated with the use of testosterone supplementation alone in aging men, we respectfully suggest that the authors consider using androgen supplement treatment strategies that avoid the potential problems associated with the 5{alpha}-reduction of testosterone to DHT. A simple, safe, and effective treatment option in this regard may be to coadminister a 5{alpha}-reductase inhibitor as adjunctive therapy with a testosterone supplement. Such an approach would prevent the DHT elevation associated with testosterone supplementation, while still allowing for testosterone to exert its beneficial metabolic and anthropometric effects. We and others have extensively studied the use of 5{alpha}-reductase inhibitors in the treatment of aging men with benign prostatic hyperplasia (5); these drugs are well tolerated and have been shown to markedly suppress the reduction of testosterone to DHT.

Footnotes

S.A.K. is currently affiliated with the Department of Urology, Weill Cornell Medical College, New York, New York.

References

  1. Pitteloud N, Mootha VK, Dwyer AA, Hardin M, Lee H, Eriksson KF, Tripathy D, Yialamas M, Groop L, Elahi D, Hayes FJ: Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care 28:1636–1642, 2005[Abstract/Free Full Text]
  2. Matsumoto AM: Andropause: clinical implications of the decline in serum testosterone levels with aging in men. J Gerontol 57A:M76–M99, 2002
  3. Thompson IM: New insights and developments from the Prostate Cancer Prevention Trial: the promise of SELECT [presentation online], 2005. Available from http://webcasts.prous.com/aua2005/article.asp?AID=22&CID=YY&CLID=2. Accessed 26 September 2005
  4. Page ST, Lin DL, Hess DL, Amory JK, Nelson PS, Matsumoto AM, Bremner WJ: Prostate tissue dihydrotestosterone, but not testosterone, levels are decreased by medical castration in normal middle-aged men (Abstract). In Proceedings of the 87th Annual Meeting of The Endocrine Society, San Diego, CA, 2005. Chevy Chase, MD, The Endocrine Society, p. 161–162, 2005
  5. McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, Albertsen P, Roehrborn CG, Nickel JC, Wang DZ, Taylor AM, Waldstreicher J: The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia: Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 338:557–563, 1998[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Diabetes CareHome page
F. Hayes
Relationship Between Testosterone Levels, Insulin Sensitivity, and Mitochondrial Function in Men: Response to Kaplan and Crawford
Diabetes Care, March 1, 2006; 29(3): 749 - 750.
[Full Text] [PDF]


This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kaplan, S. A.
Right arrow Articles by Crawford, E. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kaplan, S. A.
Right arrow Articles by Crawford, E. D.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum